• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用平衡透析技术研究影响布美他尼蛋白结合的因素。

Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique.

作者信息

Shim H J, Lee M G, Lee M H

机构信息

Dong-A Pharm. Co. Ltd, Research Laboratory, Seoul, Korea.

出版信息

J Clin Pharm Ther. 1991 Dec;16(6):467-76. doi: 10.1111/j.1365-2710.1991.tb00337.x.

DOI:10.1111/j.1365-2710.1991.tb00337.x
PMID:1770075
Abstract

Factors that influence the plasma protein binding of bumetanide were evaluated using equilibrium dialysis. It took approximately 12 h of incubation to reach an equilibrium between plasma and isotonic phosphate buffer of pH 7.4 containing 3% dextran using a Spectrapor 2 membrane (mol. wt cut-off = 12,000-14,000) in a water-bath shaker kept at 37 degrees C and at a rate of 50 oscillations per min. Bumetanide was fairly stable in both 4% human serum albumin (HSA) and in the isotonic phosphate buffer of pH 7.4 for up to 24 h. The binding of bumetanide to 4% HSA was constant (87.5 +/- 1.73%) at bumetanide concentrations ranging from 0.1 to 100 micrograms/ml. The extents of binding were 72.0, 83.3, 88.5, 90.2, 91.3 and 91.4% at albumin concentrations of 0.5, 1, 2, 3, 4 and 5 g/100 ml, respectively, and increased with a decrease in incubation temperature; the values bound were 94.6, 90.3 and 89.3% when incubated at 4, 22 and 37 degrees C, respectively. The binding of bumetanide was independent of the buffer composition used, the quantities of AAG (up to 0.32%), heparin (up to 40 units/ml), sodium azide (up to 0.5%) and anticoagulants (EDTA, heparin and citrate). The free fraction of bumetanide in rabbit plasma (2.91%) was significantly higher than in humans (1.98%) or rats (1.85%).

摘要

采用平衡透析法评估了影响布美他尼血浆蛋白结合的因素。使用Spectrapor 2膜(截留分子量 = 12,000 - 14,000),在37℃的水浴振荡器中以每分钟50次振荡的速度,大约需要12小时的孵育才能使血浆与含3%葡聚糖的pH 7.4等渗磷酸盐缓冲液达到平衡。布美他尼在4%人血清白蛋白(HSA)和pH 7.4的等渗磷酸盐缓冲液中长达24小时都相当稳定。在布美他尼浓度为0.1至100微克/毫升范围内,其与4% HSA的结合率恒定(87.5 ± 1.73%)。白蛋白浓度分别为0.5、1、2、3、4和5克/100毫升时,结合程度分别为72.0%、83.3%、88.5%、90.2%、91.3%和91.4%,且结合程度随孵育温度降低而增加;在4℃、22℃和37℃孵育时,结合值分别为94.6%、90.3%和89.3%。布美他尼的结合与所用缓冲液组成、AAG(高达0.32%)、肝素(高达40单位/毫升)、叠氮化钠(高达0.5%)和抗凝剂(EDTA、肝素和柠檬酸盐)的量无关。布美他尼在兔血浆中的游离分数(2.91%)显著高于人(1.98%)或大鼠(1.85%)。

相似文献

1
Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique.采用平衡透析技术研究影响布美他尼蛋白结合的因素。
J Clin Pharm Ther. 1991 Dec;16(6):467-76. doi: 10.1111/j.1365-2710.1991.tb00337.x.
2
Factors influencing the protein binding of YH-439 using an equilibrium dialysis technique. A new hepatoprotective agent.
Biopharm Drug Dispos. 1995 Dec;16(9):775-89. doi: 10.1002/bdd.2510160907.
3
Factors influencing the protein binding of azosemide using an equilibrium dialysis technique.
Biopharm Drug Dispos. 1995 Oct;16(7):615-26. doi: 10.1002/bdd.2510160709.
4
Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique.使用平衡透析技术研究影响新型磷酸二酯酶V抑制剂DA-8159蛋白结合的因素。
Biopharm Drug Dispos. 2000 Oct;21(7):285-91. doi: 10.1002/bdd.238.
5
Factors influencing the protein binding of IQO4, a new isoquinolinedione derivative.
Res Commun Mol Pathol Pharmacol. 2000;108(3-4):167-77.
6
Factors influencing the protein binding of vancomycin.
Biopharm Drug Dispos. 1991 Dec;12(9):637-46. doi: 10.1002/bdd.2510120902.
7
Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative.
Biopharm Drug Dispos. 1999 Oct;20(7):355-60. doi: 10.1002/(sici)1099-081x(199910)20:7<355::aid-bdd197>3.0.co;2-x.
8
Stability, blood partition, and protein binding of DA-5018, a new nonnarcotic analgesic.新型非麻醉性镇痛药DA-5018的稳定性、血液分配及蛋白结合情况
Res Commun Mol Pathol Pharmacol. 1996 Jan;91(1):97-108.
9
Blood partition and protein binding of a new neuroprotective agent for ischemia-reperfusion damage, KR-31378.
Res Commun Mol Pathol Pharmacol. 2001;110(5-6):361-70.
10
Stability, blood partition, and protein binding of NQ12, a new naphthoquinone derivative.
Res Commun Mol Pathol Pharmacol. 1999;104(2):165-72.

引用本文的文献

1
Modulation of Urate Transport by Drugs.药物对尿酸转运的调节作用。
Pharmaceutics. 2021 Jun 17;13(6):899. doi: 10.3390/pharmaceutics13060899.
2
NKCC1, an Elusive Molecular Target in Brain Development: Making Sense of the Existing Data.NKCC1,大脑发育中难以捉摸的分子靶点:解读现有数据。
Cells. 2020 Dec 4;9(12):2607. doi: 10.3390/cells9122607.
3
Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures.治疗新生儿癫痫的阳离子-氯离子共转运体的药物靶向治疗。
Epilepsia. 2014 Jun;55(6):806-18. doi: 10.1111/epi.12620. Epub 2014 May 6.
4
Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.布美他尼经静脉和口服给药后在大鼠体内的药代动力学和药效学:从胃肠道各段的吸收情况
J Pharmacokinet Biopharm. 1994 Feb;22(1):1-17. doi: 10.1007/BF02353407.